Results 181 to 190 of about 113,516 (292)

Development of new adeno-associated virus capsid variants for targeted gene delivery to human cardiomyocytes. [PDF]

Mol Ther Methods Clin Dev, 2023
Kok CY, Tsurusaki S, Cabanes-Creus M, Igoor S, Rao R, Skelton R, Liao SHY, Ginn SL, Knight M, Scott S, Mietzsch M, Fitzsimmons R, Miller J, Mohamed TMA, McKenna R, Chong JJH, Hill AP, Hudson JE, Alexander IE, Lisowski L, Kizana E.   +20 more
europepmc   +1 more source

Low-adhesion culture selection for human iPS cell-derived cardiomyocytes

Despite progress in generating cardiomyocytes from pluripotent stem cells, these populations often include non-contractile cells, necessitating cardiomyocyte selection for experimental purpose.
Tatsuya Shimizu, Katsuhisa Matsuura, Tetsutaro Kikuchi   +2 more
core   +1 more source

Prognostic role of high‐sensitivity cardiac troponin T in patients with cardiac sarcoidosis: insights from ILLUMINATE‐CS

ESC Heart Failure, Volume 12, Issue 2, Page 869-878, April 2025.
Abstract Aims The prognostic role of high‐sensitivity cardiac troponin T (hs‐cTnT) as a biomarker in patients with cardiac sarcoidosis (CS) has yet to be fully determined, especially when compared with B‐type natriuretic peptide (BNP). Methods and Results In this post‐hoc analysis of the ILLUMINATE‐CS (ILLUstration of the Management and prognosIs of ...
Yuichi Baba, Toru Kubo, Takeru Nabeta, Yuya Matsue, Takeshi Kitai, Yoshihisa Naruse, Tatsunori Taniguchi, Hidekazu Tanaka, Takahiro Okumura, Kenji Yoshioka, Hiroaki Kitaoka   +10 more
wiley   +1 more source

CX-5461 and doxorubicin activate a shared DNA damage-associated transcriptional response in human cardiomyocytes. [PDF]

G3 (Bethesda)
Paul S, Gutiérrez JA, Bogar AR, Matthews ER, Ward MC.   +4 more
europepmc   +1 more source

Computational design of custom therapeutic cells to correct failing human cardiomyocytes. [PDF]

Front Syst Biol, 2023
Tieu A, Phillips KG, Costa KD, Mayourian J.   +3 more
europepmc   +1 more source

Commonalities of platelet dysfunction in heart failure with preserved ejection fraction and underlying comorbidities

ESC Heart Failure, Volume 12, Issue 2, Page 1013-1028, April 2025.
Abstract Heart failure with preserved ejection fraction (HFpEF) is characterized by a lack of a specific targeted treatment and a complex, partially unexplored pathophysiology. Common comorbidities associated with HFpEF are hypertension, atrial fibrillation, obesity and diabetes.
Giorgia D'Italia, Blanche Schroen, Judith M.E.M. Cosemans   +2 more
wiley   +1 more source

Chamber-specific chromatin architecture guides functional interpretation of disease-associated Cis-regulatory elements in human cardiomyocytes. [PDF]

Nat Commun
Haydar S, Bednarz R, Laurette P, Sobitov I, Díaz I Pedrosa N, Videm P, Lueneburg T, Kuß S, Lahm H, Dreßen M, Krane M, Schmidt C, Grüning BA, Voigt N, Streckfuss-Bömeke K, Gilsbach R.   +15 more
europepmc   +1 more source

Propofol synergizes with circAPBB2 to protect against hypoxia/reoxygenation-induced oxidative stress, inflammation, and apoptosis of human cardiomyocytes. [PDF]

Immun Inflamm Dis, 2023
Jin C, Yuan S, Piao L, Ren M, Liu Q.
europepmc   +1 more source

The effects of sodium–glucose cotransporter 2 inhibitors on the ‘forgotten’ right ventricle

ESC Heart Failure, Volume 12, Issue 2, Page 1045-1058, April 2025.
Abstract With the progress in diagnosis, treatment and imaging techniques, there is a growing recognition that impaired right ventricular (RV) function profoundly affects the prognosis of patients with heart failure (HF), irrespective of their left ventricular ejection fraction (LVEF).
Liangzhen Qu, Xueting Duan, Han Chen
wiley   +1 more source

Prime editing corrects the dilated cardiomyopathy causing RBM20-P633L-mutation in human cardiomyocytes. [PDF]

Mol Ther Nucleic Acids
Roman A, Zimmer A, Gotthardt M, Steinmetz LM, Kühn R, Dang T.   +5 more
europepmc   +1 more source